GlassScriptPhysician profile
Anna Flor C Salcedo
NPI 1053486472
$10,234.38
in general payments reported to CMS, 2019-2025
45 companies · $2,915 in 2025
The $2,915 reported for 2025 was more than what 96% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $369 · 2020: $22.04 · 2021: $500 · 2022: $1,682 · 2023: $2,302 · 2024: $2,445 · 2025: $2,915.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,662.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,661.69 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,206.24 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Novo Nordisk INC | $1,005.67 | 2021-2025 | Rybelsus, Ozempic, Wegovy |
| Bayer Healthcare Pharmaceuticals INC. | $986.31 | 2021-2025 | |
| Novartis Pharmaceuticals Corporation | $741.03 | 2022-2025 | |
| Abbvie INC. | $711.11 | 2022-2025 | Ubrelvy, Vraylar, Qulipta |
| Gilead Sciences, INC. | $551.00 | 2023-2025 | Livdelzi, Vemlidy |
| Pfizer INC. | $479.16 | 2020-2025 | |
| Astellas Pharma US INC | $434.52 | 2022-2025 | Veozah, Myrbetriq |
| Lilly USA, LLC | $428.05 | 2021-2025 | Jardiance, Mounjaro, Zepbound |
| Boehringer Ingelheim Pharmaceuticals, INC. | $399.17 | 2021-2025 | Jardiance |
| Amgen INC. | $342.31 | 2019-2025 | Repatha, Otezla, Repatha |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $305.74 | 2022-2025 | Xifaxan, Trulance |
| Mannkind Corporation | $289.53 | 2021-2025 | |
| Glaxosmithkline, LLC. | $259.22 | 2022-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Corcept Therapeutics | $218.46 | 2024-2025 | Korlym |
Show all 45 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anna Flor Salcedo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.